163 related articles for article (PubMed ID: 34243797)
1. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.
Lischalk JW; Blacksburg S; Mendez C; Repka M; Sanchez A; Carpenter T; Witten M; Garbus JE; Evans A; Collins SP; Katz A; Haas J
Radiat Oncol; 2021 Jul; 16(1):126. PubMed ID: 34243797
[TBL] [Abstract][Full Text] [Related]
2. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
4. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
6. Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy.
Feagins LA; Kim J; Chandrakumaran A; Gandle C; Naik KH; Cipher DJ; Hou JK; Yao MD; Gaidos JKJ
Inflamm Bowel Dis; 2020 Apr; 26(5):728-733. PubMed ID: 31412114
[TBL] [Abstract][Full Text] [Related]
7. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques.
Murphy CT; Heller S; Ruth K; Buyyounouski MK; Weinberg D; Uzzo RG; Plimack E; Kutikov A; Chen DYT; Horwitz EM
Pract Radiat Oncol; 2015; 5(3):e215-e222. PubMed ID: 25424586
[TBL] [Abstract][Full Text] [Related]
8. Proctitis following stereotactic body radiation therapy for prostate cancer.
Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
[TBL] [Abstract][Full Text] [Related]
9. Low Toxicity in Inflammatory Bowel Disease Patients Treated With Abdominal and Pelvic Radiation Therapy.
White EC; Murphy JD; Chang DT; Koong AC
Am J Clin Oncol; 2015 Dec; 38(6):564-9. PubMed ID: 24401668
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands.
Hurwitz JC; Haas J; Mendez C; Sanchez A; Santos VF; Akerman M; Carpenter T; Tam M; Katz A; Corcoran A; Mahadevan A; Taneja SS; Lepor H; Lischalk JW
Pract Radiat Oncol; 2024; 14(3):241-251. PubMed ID: 37984713
[TBL] [Abstract][Full Text] [Related]
11. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
12. Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
Gurka MK; Chen LN; Bhagat A; Moures R; Kim JS; Yung T; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2015 Feb; 10():44. PubMed ID: 25890265
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Meier RM; Bloch DA; Cotrutz C; Beckman AC; Henning GT; Woodhouse SA; Williamson SK; Mohideen N; Dombrowski JJ; Hong RL; Brachman DG; Linson PW; Kaplan ID
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):296-303. PubMed ID: 30191864
[TBL] [Abstract][Full Text] [Related]
14. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
15. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study.
D'Agostino GR; Mancosu P; Di Brina L; Franzese C; Pasini L; Iftode C; Comito T; De Rose F; Guazzoni GF; Scorsetti M
Am J Clin Oncol; 2020 Sep; 43(9):628-635. PubMed ID: 32889832
[TBL] [Abstract][Full Text] [Related]
20. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
